UNIVERSITY OF BIRMINGHAM (GB);CHILDRENS MEDICAL CENTER CORPORATION;CHILDREN'S MEDICAL CENTER CORPORATION
发明人:
UMETSU, DALE T.,DEKRUYFF, ROSEMARIE H.,CHANG, YA-JEN,ILLARIONOV, PETR
申请号：
EP11787213
公开号：
EP2575824A4
申请日:
2011.05.24
申请国别(地区):
EP
年份:
2014
代理人:
摘要：
The inventors demonstrate that treatment of young, suckling mice with a glycolipid derived from Helicobacter pylori activates NKT cells in a CD1d-restricted fashion, and is protective against AHR in a model of allergen-induced asthma. The inventors further found that this protective effect can be transferred by NKT cells exposed to the glycolipid, and is associated with the expansion of a suppressive double-negative NKT cells and Foxp3+ TReg cells. The inventors also demonstrate herein that pre-treatment of adult mice with a glycolipid derived from Helicobacter pylori partially suppresses airway hyperreactivity and inhibits BAL inflammation in an ozone-exposure model. Accordingly, provided herein are compositions and methods for the treatment and prevention of inflammatory diseases, such as asthma or autoimmune diseases, in a subject in need thereof.
